We’re shortening the gap between product innovation and effective patient outcomes
Cancer & Disease Genetics
Taking the wide-angle look at defeating cancer requires much more than analytics. Accessing current data points converging with our powered platform also targets the emergence and presence of new forms of cancers.
While taking mutation and genetic variances as key indicators for disease mapping, we’re infusing the data points into practical and proactive elements that will cut down the lead time for lead candidate selection. By creating predictive key indicators, we’ll also show how your lead candidate will perform in the fight towards cancers and diseases.
Virtual Clinical Trials
Lead candidate efficacy and survivability requires robust collaboration with the patient community. Now that the world is much more diverse and sprawled than ever, creating programs that are inclusive becomes a greater challenge. By virtualizing the clinical trial process, take your innovation to the patient where they reside.
Institutions, payer systems, and administrations have been focusing on harmonizing the ability to create transparent processes that will readily mobilize patient collaboration. With developing proactive intelligence data points, we’re creating new pathways where new programs can be supportive of a new healthcare landscape.
Mobilizing innovation that reaches mission objectives.
As the world shifts to defend against new health threats, agencies are grappling with new ways to overcome those challenges. Agile convergence of digital and scientific innovation becomes the vehicle of delivering outcomes-based approaches that achieves mission objectives. We’re not just innovators, we’re also creating entrepreneurial structure into agencies that will increase strength and expansion into programs that will put your group into leading thought. How will you overcome the challenges fulfilling your next mission objectives?
February 27, 2019, Lawrence, MA- Life Science company Rubix LS growth has now expanded to encompass a new direction for the organization; Digital Life Sciences. As new tactics to deploy discovery towards patient-centric product development gains momentum, this new...
Representation of minorities in clinical trials is at an all time low. Life saving treatment options not known to the diverse background continues to increase mortality rates.
Lawrence Award Program Honors the Achievement LAWRENCE, MA December 17, 2018 -- Rubix LS has been selected for 2018 Best of Lawrence Award in the Research and Product Development category by the Lawrence Award Program. Each year, the Lawrence Award Program identifies...
Let’s start the conversation with your goals in mind.